May 6th 2024
During a Case-Based Roundtable® event, Ulka Vaishampayan, MBBS, discussed the safety and quality-of-life data for ipilimumab plus nivolumab in patients with advanced renal cell carcinoma in the second article of a 2-part series.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
The Efficacy of AGS-003 in mRCC
March 13th 2014Robert Figlin, MD, FACP, professor of medicine and biomedical sciences, Steven Spielberg Family Chair in Hematology Oncology, Cedars-Sinai Medical Center, discusses results from a single-arm phase II trial of the autologous dendritic cell immunotherapy AGS-003 plus standard treatment for patients with newly-diagnosed metastatic renal cell carcinoma
Watch
Sunitinib in Combination With Temsirolimus for mRCC
March 8th 2014Nizar M. Tannir, MD, FACP, associate professor, deputy department chair, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses a phase I trial of sunitinib and temsirolimus in patients with metastatic renal cell carcinoma.
Watch
AR Findings Highlight Detailed Tumor-Profiling Study
March 7th 2014A wide-ranging analysis of more than 5500 breast cancer tumors that combined genomic and protein expression testing has identified promising targets to explore for treating patients with poor prognoses, with particularly notable findings involving androgen receptor (AR) expression.
Read More
The Role of Cytoreductive Nephrectomy in Patients With Synchronous Metastases From RCC
February 11th 2014Brian Rini, MD, associate professor, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, discusses the role of cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma (RCC).
Watch
Patients With High PD-L1 Expression in mRCC are Less Sensitive to VEGF-Targeted Drugs
February 4th 2014According to a retrospective analysis of the phase III COMPARZ trial, high tumor expression of the protein PD-L1 (programmed cell death 1 ligand 1) is independently associated with shorter overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC) receiving treatment with vascular endothelial growth factor (VEGF)-targeted therapy.
Read More
The Impact of Angiotensin System Inhibitors on Outcomes in Patients with mRCC
January 31st 2014Rana R. McKay, MD, a clinical oncology fellow at Dana-Farber Cancer Institute, Boston, Massachusetts, discusses a trial that analyzed overall survival in patients with metastatic renal cell carcinoma who used angiotensin system inhibitors.
Read More
Whole-Genome Sequencing Identifies Actionable Mutations in HCC
January 17th 2014A research team at Cold Spring Harbor Laboratory in New York has succeeded in identifying the most common genetically altered genes and the major oncogenic drivers in hepatitis B virus-associated hepatocellular carcinoma (HCC).
Read More
Treating Renal Cell Carcinoma in 2013
January 6th 2014Over the past few years, seven new drugs have gained approval from the FDA for the treatment of patients with metastatic renal cell carcinoma (RCC). The advent of these molecularly targeted therapies has significantly improved the standard of care for patients with RCC.
Read More
AGS-003 Activates Promising Immune Response in mRCC
November 18th 2013AGS-003, an investigational autologous dendritic cell vaccine, successfully activated a cytotoxic T cell response that correlates with a prolongation in survival for patients with metastatic renal cell carcinoma (mRCC), according to an analysis presented at the 2013 Annual Meeting of the Society for Immunotherapy of Cancer.
Read More
Treatment of Advanced Renal Cell Carcinoma
October 26th 2013The treatment of advanced renal cell carcinoma (RCC) remains a major challenge for clinicians. However, according Daniel J. George, MD, the progress being made in understanding RCC tumor biology is already helping us to discover better, more effective treatments.
Read More
Pazopanib Poses Less Potential for Side Effects in RCC
October 7th 2013Though pazopanib and sunitinib are relatively similar in terms of efficacy in the treatment of advanced renal cell carcinoma, the former appears to cause fewer toxic side effects than the latter, suggesting that patients could experience a greater quality of life and the same treatment benefit with pazopanib as opposed to sunitinib.
Read More
Evolution of Care in Advanced Kidney Cancer
September 19th 2013With seven targeted therapies approved for metastatic renal cell carcinoma (RCC), researchers and drug developers are now focusing on understanding the best way to sequence these therapies—and on identifying predictive biomarkers of response.
Read More